- Research article
- Open Access
- Open Peer Review
Initial experience with off-pump left ventricular assist device implantation in single center: retrospective analysis
© Awad et al; licensee BioMed Central Ltd. 2010
- Received: 4 October 2010
- Accepted: 6 December 2010
- Published: 6 December 2010
We hypothesize that implantation of left ventricular assist device through off-pump technique is feasible and has a comparable result to implantation on cardiopulmonary bypass and could improve one-year survival.
This retrospective, observational, single-center study was conducted on 29 consecutive patients at our institution who underwent off-pump left ventricular assist device implantation by a single surgeon.
Twenty-seven procedures were performed successfully using the off-pump technique. The survival rate was 92% at 30 days, 76% at 90 days, and 67% at one year. We compared the one-year survival of different implantation periods, and divided our study into three time intervals (2004-2005, 2006, and 2007). There was a trend in reduction in number of deaths over one year that demonstrated a decrease in death rate from 50% to 17%, as well as improvement in our experience over time. However, this trend is not statistically significant (p = 0.08) due to limited sample size.
Based upon our findings, off-pump left ventricular assist device implantation is a feasible surgical technique, and combining this technique with improved device technology in the future may provide even greater improvement in patient outcomes.
- Destination Therapy
- Left Ventricular Assist Device Implantation
- Outflow Graft
- Sewing Cuff
- Kaolin Activate Clotting Time
Left ventricular assist devices were approved as a bridge to transplantation therapy (BTT) in 1998 . In 2001, they became a destination therapy in the United States . Perioperative complications result from a combination of three factors: 1) intrinsic heart failure with secondary organ damage; 2) long-term effect of the implanted device; and 3) surgical techniques employed, including cardiopulmonary bypass (CPB). CPB has advantages such as inspecting left ventricle for thrombus, hemodynamic resuscitation, and removing fluid, including ultrafiltrations on CPB, but it may have unwanted effects as well, such as increasing systemic inflammatory response and transfusion requirements. To date, the experimental and clinical data comparing on-pump and off-pump coronary surgery suggest an affected cardiac function in favor of off-pump operations, which might be related to greater myocardial damage during hypothermic CPB operations . We believe in order to improve the clinical outcome there is a need to ameliorate one of these factors. Although previous studies have demonstrated an advantage in reducing morbidity in off-pump coronary artery bypass-graft (CABG) patients, but not reducing mortality, it can be reasonably concluded that the same may hold true in sicker patients receiving off-pump left ventricular assist device (OP LVAD) implantation in high-risk heart failure patients [4, 5]. This article analyzes our experience with the initial series of 29 consecutive patients undergoing placement of LVAD as both BTT and destination therapy, without the use of CPB, and measures postoperative mortality up to one year.
After obtaining approval from the Institutional Review Board, we retrospectively reviewed data from patients who were scheduled to undergo OP LVAD implantation at The Ohio State University Medical Center between October 2004 and May 2007. Postoperative outcomes included ventilation hours and postoperative hospital stays (days). Mean and standard deviation were calculated . Early postoperative bleeding was in accordance with Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) guidelines to ensure that the descriptions of adverse events in studies using mechanical assist devices are universal. The types of implanted devices included: 14 HeartMate II, 10 HeartMate XVE, 2 IVAD, and 1 DeBakey. The incidence rates of complications were calculated. Patient mortality was calculated at three time periods: 30 days, 90 days, and one year postoperatively. We performed a univariate analysis of all patient data to obtain descriptive statistics. Comparisons across categories were performed through Fisher's exact test.
We reviewed the intraoperative anesthetic chart in all study patients, which included the monitoring of arterial blood pressure, heart rate, pulmonary artery pressure, and central venous pressure. An intraoperative transesophageal echocardiogram was employed for assessment of right and left ventricular function, exclusion of associated pathologies that preclude OP implantation (intra-atrial shunts, ventricular thrombus, severe aortic insufficiency), and guidance in de-airing of the heart once the device was implanted. Heparin was administered to keep the kaolin activated clotting time (ACT) above 300 seconds. Inotropic medications were used to support right ventricular function according to the treating anesthesiologist. There was no point of care testing for transfusion requirements, which were determined by the treating physicians. The treating physician made clinical decisions about the transfusion of PRBCs or other blood products without clear logarithms.
A detailed surgical technique of OP LVAD implantation was first perfected after more than 30 intracorporeal ventricular assist devices were implanted off pump in bovine and ovine models for various studies including heart failure (unpublished data) due to the time- and cost-intensive nature of placing animals on CPB . Our team's experience with this novel idea was then translated to our patients. Before starting the procedure, we performed transesophageal echocardiography to monitor underlying contraindications to OP LVAD implantation, such as severe aortic regurgitation, right-to-left shunts with worsening hypoxemia, and/or thrombus formation. Also, a primed bypass circuit was available in case of an emergent change to an on-pump procedure, such as hemodynamic instability. After median sternotomy, a pericardial well was created and a pre-peritoneal pocket formed by tunneling the driveline through the skin, with placement of the device in the pocket. After successful heparinization (ACT of 300 seconds), the ascending aorta was cannulated with an Embol-X cannula to collect debris, while the outflow graft was sewn into the ascending aorta in the standard fashion with a partial cross clamp. Opening of the inferior right pericardial edge to the inferior vena cava, with release of stay sutures, allowed cardiac positioning with the apex out of the chest as in an off-pump CABG procedure. Meanwhile, the patient was placed in the Trendelenburg position, slightly rotated towards the surgeon. An apical sewing cuff was sewn into the left ventricular apex by passing a large silk stitch into the center of the apex, while 2-0 pledgetted Ticron mattress sutures were placed in the apex and passed through the cuff. Three large Foley catheters were prepared and ready for use. The first was moistened and passed into the inflow elbow of the ventricular assist device, positioned so the tip exits the proximal end of the cannula. Next it was inflated with 10 to 15 ml of saline to plug the lumen of the cannula, while the proximal end of the Foley was clamped to stop back bleeding. The second Foley catheter was prepared similarly and used to help core the LV apex, making sure it was inflated and deflated while still providing occlusion of the lumen. The final Foley catheter was prepared similarly and used in case of rupture of one of the first two Foley balloons. The outflow graft was then attached to the LVAD and back bled to help de-air the pump. The apex was then cored with a coring knife that was passed through the Foley and silk stay suture. An incision was made into the LV apex and the Foley was placed into the cavity. The second Foley was inflated with 15 ml of saline and traction applied to bring the apex up and out of the chest cavity. The apex was cored without entering the Foley, and scissors were used to remove the remaining cuff. After coring the apex, the inflow elbow was connected by deflating and removing the balloon. To minimize ejection of blood out of the hole during balloon removal and inflow graft connection, the heart was arrested for 1 to 2 minutes with adenosine intravenous bolus (6 to 12 mg IV) or fibrillated using DC fibrillator (Cardiovascular Instrument Corp., Model 2039, Wakefield, MA, USA). A linear incision was made through the diaphragm, allowing the pump to sit in the preperitoneal space and then the diaphragm was closed around the inflow cannula, while the pump was back bled again from the aortic side for de-airing.
Demographics, hemodynamic values, and perioperative homeostatic parameters for off-pump device implantation for 27 patients.
SD ± 11.9
Male 18, female 9
Dilated CM* 10, Ischemic heart disease (IHD) 9, Postpartum CM* 1, Familial CM* 1, Congenital 1, Unknown 1, Drug-induced CM* 4
Indication of operation
DT† 19; BT‡ 8
Cardiac output (liters/minute)
SD ± 1
Ejection fraction (%)
SD ± 6
SD ± 1
Mean pulmonary artery pressure (mmHg)
SD ± 7
Preoperative inotropic support
No 10; Yes 17
Preoperative Homeostatic Parameters
SD ± 1
SD ± 4
Platelet count (×1000/ml)
SD ± 69
SD ± 24
SD ± 0.5
Statistical analysis was performed on 27 patients. Of those analyzed, 4 patients presented with cardiogenic shock. No patients required unplanned right VAD placement. Subsequently, 5 patients had a cardiac transplantation. Of these 5 patients, 2 had a heart transplant 1 year after LVAD insertion; 1 patient was transplanted 2 months after the LVAD placement and died 8 months posttransplant from graft rejection; and the other 2 patients underwent heart transplants 2 and 5 months after LVAD implantation. We excluded those 3 patients who received transplants after less than one year when calculating the mortality. Two patients categorized as destination therapy became transplant eligible.
Postoperative outcome, complications, and mortality in 27 patients undergoing off-pump left ventricular assist device implantation.
Postoperative Hospital Stay (days)
Number of Incidence/Total
Mortality at 30 days
Mortality at 90 days
Mortality at 1 year
Data in tertiles over three-year period.*
Year of OP LVAD
Number of deaths at 1 year postoperative/Total
Percent of death
This study reports the feasibility of a surgical technique for placement of LVADs through a median sternotomy incision without the use of CPB at our institution. This technique was used in the implantation of several different LVAD devices and was successful in 27 of 29 consecutive patients. Our initial anesthetic learning experience with OP LVAD insertion was satisfactory. Our one-year survival of OP LVAD insertion was 67%, which proved better than the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial (52%) and the post-REMATCH era (56%). We believe this may be related to the avoidance of CPB, although this hypothesis has yet to be proven [2, 4]. This was also comparable to the one-year survival of the most recent large trial using continuous-flow LVAD (68%), and better than pulsatile flow LVAD (52%), both on CPB . However, our results were slightly less favorable compared with the one-year survival (73%) seen in recent trials conducted by Pagani et. al, using continuous-flow rotary LVAD using CPB in BTT patients, which correlated consistent improvements in patient outcome with newer device technology . However, we believe that avoidance of CPB combined with improvements in device technology could provide greater benefits in future clinical outcomes.
In our series of 27 OP LVAD insertions, 9 patients experienced postoperative bleeding leading to transfusion of more than 4 units of PRBCs in the first 24 hours, a rate better than the historical REMATCH trial group (38%) in which all procedures were performed using CPB. In another study, using the same definition for massive perioperative bleeding as the INTERMACS registry and our study, which evaluated 222 patients with a Novacor LVAD implanted during CPB, massive perioperative bleeding occurred in 97 out of 222 patients and half of the total population returned for reoperation [9, 10]. We believe this may be related to CPB and its deleterious effect and/or the Novacor device. However, this claim warrants further investigation in a randomized control trial with newer technology like the HeartMate II LVAD, which has different characteristics of flow.
Despite our initial encouraging results, this study has a number of limitations. While it does represent a consecutive series of patients who underwent the same surgical technique, it is a retrospective study that consists of a limited number of subjects and the hypothesis was generated after the surgical technique was established. In addition, due to the retrospective nature of the data collection, the transfusion trigger was not standardized within the first 24 hours postoperatively. Lastly, we could not do a case match control group from historical data in our institution for two reasons: 1) there was an upgrade in device technology, and 2) all of these cases were performed by one surgeon, who was using only this technique in 27 consecutive patients, and the historical group cases were performed by different surgeons on the CPB.
As we performed more procedures off pump, the perioperative team became more familiar with the surgical technique and anesthetic requirement, and this was reflected in our data, showing improvement over time in one-year survival post implantation. The death rate over one year decreased from 50% to 17% in our small series, although this trend was not statistically significant due to limitations in sample size; however, many events including postoperative care, etc. can affect the one year outcome. It did show promise in helping high-risk heart failure patients, and the next step is to perform this technique in a larger clinical trial to validate this hypothesis, which we believe is worthwhile in improving clinical outcomes of cases done off CPB. This would allow confirmation of our findings, while addressing the limitations of our retrospective analysis. In conclusion, based upon our findings, OP LVAD implantation is a feasible surgical technique, and combining this technique with improved device technology could provide even greater improvement in patient outcomes in the future.
We wish to acknowledge Tammy Yanssens, transplant coordinator at The Ohio State University Medical Center Ross Heart Hospital, for helping with data collection, and Keri J. Hudec, technical editor at The Ohio State University Medical Center Department of Anesthesiology.
- Goldstein DJ, Oz MC, Rose EA: Implantable left ventricular assist devices. N Engl J Med. 1998, 339: 1522-1533. 10.1056/NEJM199811193392107.View ArticlePubMedGoogle Scholar
- Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W: Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001, 345: 1435-1443. 10.1056/NEJMoa012175.View ArticlePubMedGoogle Scholar
- Puskas JD, Williams WH, Duke PG, Staples JR, Glas KE, Marshall JJ: Off-pump coronary artery bypass grafting provides complete revascularization with reduced myocardial injury, transfusion requirements, and length of stay: a prospective randomized comparison of two hundred unselected patients undergoing off-pump versus conventional coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2003, 125: 797-808. 10.1067/mtc.2003.324.View ArticlePubMedGoogle Scholar
- Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano MA: Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation. 2007, 116: 497-505. 10.1161/CIRCULATIONAHA.107.691972.View ArticlePubMedGoogle Scholar
- Raja SG, Dreyfus GD: Impact of off-pump coronary artery bypass surgery on postoperative bleeding: current best available evidence. J Card Surg. 2006, 21: 35-41. 10.1111/j.1540-8191.2006.00164.x. discussion 42-43View ArticlePubMedGoogle Scholar
- Sun BC, Firstenberg MS, Louis LB, Panza A, Crestanello JA, Sirak J: Placement of long-term implantable ventricular assist devices without the use of cardiopulmonary bypass. J Heart Lung Transplant. 2008, 27: 718-721. 10.1016/j.healun.2008.03.020.View ArticlePubMedGoogle Scholar
- Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D: Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009, 361: 2241-2251. 10.1056/NEJMoa0909938.View ArticlePubMedGoogle Scholar
- Pagani FD, Miller LW, Russell SD, Aaronson KD, Ranjit J, Boyle AJ: Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. JACC. 2009, 54: 312-321.View ArticlePubMedGoogle Scholar
- Richenbacher WE, Naka Y, Raines EP, Frazier OH, Couper GS, Pagani FD: Surgical management of patients in the REMATCH trial. Ann Thorac Surg. 2003, 75: S86-S92. 10.1016/S0003-4975(03)00485-5.View ArticlePubMedGoogle Scholar
- Butler J, Howser R, Portner PM, Pierson RN: Body mass index and outcomes after left ventricular assist device placement. Ann Thorac Surg. 2005, 79: 66-73. 10.1016/j.athoracsur.2004.06.047.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.